65,437 trials
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Percutaneous Closure of Arteriotomy in Common Femoral Artery
Primary: Major Vascular Complications Directly Related to Device — 0 percentage of participants
Osteoporosis · Osteopenia
Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2
Homozygous Familial Hypercholesterolemia (HoFH)
Primary: LDL-Cholesterol (mg/dL) — 396.0; 481.4 mg/dL — p=0.005
Acute Myeloid Leukemia · Acute Myelogenous Leukemia
Primary: Kaplan Meier Estimates for One Year Survival — 3.00; 9.61; 13.67 months — p=0.119
Juvenile Idiopathic Arthritis
Primary: Apparent Oral Clearance (CL/F) — 28.09; 25.48; 20.53 liter per hour
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Cocaine Dependence
Primary: Change From Baseline in the Binding Potential of [11C]Raclopride — -13.7; -5.8 ratio — p=0.003
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes — 75; 83; 41; 49 titer
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin) — -1.146; -0.529 percentage of glycosylated haemoglobin — p=<0.0001
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) Within 1 Month After 13vPnC Vaccination — 0; 7; 0; 0 Percentage…
Hepatitis C, Chronic
Primary: Change From Baseline in Viral Load (log10 Reduction) at Week 12 — -3.26; -3.27 log (IU/mL) — p=0.978
Acute Ischemic Stroke
Primary: Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) — 2.17; 2.37 mL — p=0.779
Fibromyalgia
Primary: Change From Baseline in Pain Numeric Rating Scale by Week — 6.7; -2.1; -1.8; -2.1 Number
Circumference Reduction
Primary: Lay End User Ability to Correctly Choose Suitably Qualified Individuals to Get the ZERONA Z6 Treatments — 22 participants